CTIC Share Price

Open 3.39 Change Price %
High 3.50 1 Day 0.04 1.18
Low 3.37 1 Week -0.11 -3.12
Close 3.42 1 Month 0.02 0.59
Volume 139537 1 Year 3.09 936.36
52 Week High 6.48
52 Week Low 0.32
CTIC Important Levels
Resistance 2 3.54
Resistance 1 3.49
Pivot 3.43
Support 1 3.35
Support 2 3.30
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
DCTH 0.14 -6.67%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPSL 0.14 55.56%
LOCM 0.09 50.00%
HAUP 0.10 42.86%
SYMX 0.50 38.89%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPNT 11.40 24.73%
IFON 0.61 24.49%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DCIX 0.19 -58.70%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cell Therapeutics, Inc. (NASDAQ: CTIC)

CTIC Technical Analysis 2
As on 26th Jul 2017 CTIC Share Price closed @ 3.42 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.69 & Strong Sell for SHORT-TERM with Stoploss of 3.65 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for July
1st Target up-side 4.13
2nd Target up-side 4.7
3rd Target up-side 5.27
1st Target down-side 2.49
2nd Target down-side 1.92
3rd Target down-side 1.35
CTIC Other Details
Segment EQ
Market Capital 134819600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
CTIC Latest News
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.